| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16,7 M € | -4.2% | 17,4 M € | -2.5% | 17,9 M € | +1.2% | 17,7 M € | +6.5% | 16,6 M € | +9.8% | 15,1 M € | -11.5% | 17,1 M € | +15.4% | 14,8 M € | -4.6% | 15,5 M € | -4.5% | 16,2 M € | +15.1% | 14,1 M € | +19.2% | 11,8 M € | +6.9% | 11,1 M € | +1.0% | 10,9 M € | -1.3% | 11,1 M € | +5.2% | 10,5 M € | +11.3% | 9,5 M € | -3.5% | 9,8 M € | |
| EBITDA | 556,6 k € | -70.1% | 1,9 M € | -10.0% | 2,1 M € | +12.9% | 1,8 M € | -27.7% | 2,5 M € | +66.6% | 1,5 M € | -39.5% | 2,5 M € | +890.4% | 253,6 k € | -77.4% | 1,1 M € | -45.2% | 2,0 M € | +2.4% | 2,0 M € | +36.5% | 1,5 M € | +31.0% | 1,1 M € | +43.3% | 779,8 k € | -36.9% | 1,2 M € | +39.5% | 885,9 k € | +81.5% | 488,1 k € | -5.0% | 513,9 k € | |
| Operating profit | -739,2 k € | -231.7% | 561,1 k € | +47.5% | 380,3 k € | +51.8% | 250,5 k € | -80.6% | 1,3 M € | +665.5% | 168,3 k € | -79.7% | 828,0 k € | +279.0% | -462,5 k € | -178.1% | 592,2 k € | -56.2% | 1,4 M € | +5.5% | 1,3 M € | +61.6% | 793,3 k € | +118.4% | 363,3 k € | +105.7% | 176,6 k € | -59.5% | 435,8 k € | -50.6% | 882,9 k € | +231.0% | 266,8 k € | +224.1% | 82,3 k € | |
| Profit/loss | -1,1 M € | -842.0% | 145,6 k € | +698.6% | -24,3 k € | +58.3% | -58,3 k € | -107.0% | 837,0 k € | +1634.6% | -54,5 k € | -110.7% | 509,6 k € | +173.9% | -689,6 k € | -360.8% | 264,4 k € | -72.7% | 967,0 k € | -7.1% | 1,0 M € | +89.5% | 549,2 k € | +2039.6% | 25,7 k € | +116.9% | -151,7 k € | -183.7% | 181,2 k € | -76.7% | 777,7 k € | +231.3% | 234,7 k € | -90.2% | 2,4 M € | |
| Equity | 4,4 M € | -19.7% | 5,5 M € | +2.7% | 5,3 M € | -0.5% | 5,4 M € | -1.1% | 5,4 M € | +18.2% | 4,6 M € | -7.1% | 4,9 M € | +11.5% | 4,4 M € | -13.5% | 5,1 M € | -4.4% | 5,4 M € | +22.0% | 4,4 M € | +31.1% | 3,3 M € | +4.7% | 3,2 M € | +0.8% | 3,2 M € | -4.6% | 3,3 M € | +5.8% | 3,1 M € | +20.2% | 2,6 M € | +9.9% | 2,4 M € | |
| Total assets | 10,1 M € | -12.9% | 11,6 M € | -7.4% | 12,5 M € | -9.9% | 13,9 M € | -12.6% | 15,9 M € | +17.0% | 13,6 M € | -13.1% | 15,6 M € | -3.3% | 16,2 M € | +2.6% | 15,8 M € | +5.7% | 14,9 M € | +11.4% | 13,4 M € | +6.6% | 12,6 M € | +8.5% | 11,6 M € | +0.8% | 11,5 M € | +1.5% | 11,3 M € | +53.6% | 7,4 M € | +17.0% | 6,3 M € | -23.4% | 8,2 M € | |
| Cash | 407,7 k € | -41.6% | 698,0 k € | +6.9% | 652,9 k € | +32.8% | 491,8 k € | -70.0% | 1,6 M € | +339.5% | 372,8 k € | -45.5% | 684,6 k € | +2.6% | 667,4 k € | -37.8% | 1,1 M € | -27.2% | 1,5 M € | -38.9% | 2,4 M € | +15.6% | 2,1 M € | +144.9% | 852,0 k € | +98.2% | 429,8 k € | -20.0% | 537,3 k € | +47.4% | 364,4 k € | +40.0% | 260,3 k € | +181.2% | 92,6 k € | |
| Debts | 5,7 M € | -6.0% | 6,0 M € | -15.2% | 7,1 M € | -16.1% | 8,5 M € | -18.8% | 10,4 M € | +16.4% | 9,0 M € | -16.3% | 10,7 M € | -8.9% | 11,7 M € | +10.4% | 10,6 M € | +12.2% | 9,5 M € | +7.0% | 8,9 M € | -0.9% | 8,9 M € | +13.4% | 7,9 M € | -2.2% | 8,1 M € | +3.3% | 7,8 M € | +106.1% | 3,8 M € | +15.2% | 3,3 M € | -41.9% | 5,7 M € | |
| Staff | 80,9 | 84,1 | 85,1 | 79,8 | 76,4 | 77,4 | 75,5 | 70,5 | 68,6 | 66,8 | 63,8 | 58,4 | 56,3 | 61 | 59 | 57,7 | 57,6 | 59,3 | ||||||||||||||||||
Public limited company · Ottignies-Louvain-la-Neuve · incorporated on 23/05/1996 · 80,9 ETP
Public limited company loss-making in the latest fiscal year. Cash position declining (-41.6%).
Solid counterparty for a standard engagement.
DIAsource ImmunoAssays S.A. is a Public limited company incorporated in 1996. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Ottignies-Louvain-la-Neuve. It employs on average 80,9 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette